Sumitomo Pharma Hits Day High with 7.95% Surge in Stock Price

Sumitomo Pharma Co., Ltd. has experienced a significant uptick in its stock performance, gaining 7.95% on May 29, 2026. The stock reached an intraday high of JPY 1,640.00, reflecting strong market activity. Over the past year, Sumitomo Pharma has outperformed the Japan Nikkei 225, delivering a remarkable return of 115.54% compared to the index's 72.58%. The company's financial metrics indicate robust operational health, with a net profit of JPY 96,471 million and an impressive return on equity (ROE) of 38.10%. Additionally, Sumitomo Pharma reported a notable operating cash flow of JPY 53,277 million, showcasing its ability to generate cash effectively. The stock's price-to-earnings (P/E) ratio stands at 7.00, suggesting an attractive valuation relative to its earnings. Despite a year-to-date decline of 29.98%, the company has shown resilience with a 1.26% growth in net sales and positive results for five consecutive quarters. As a mid-cap player in the pharmaceuticals and biotechnology sector, Sumitomo Pharma continues to demonstrate strong fundamentals and market presence.